摘要
目的:观察静灵口服液联合盐酸托莫西汀治疗注意缺陷多动障碍(ADHD)的临床疗效。方法:将80例ADHD患儿随机分为对照组和治疗组各40例。对照组给予盐酸托莫西汀治疗,治疗组在对照组的基础上加用静灵口服液治疗。治疗12周后观察2组临床疗效,并采用Conner简明症状量表(ASQ)和SNAP-Ⅳ量表对2组治疗前后注意力、控制力进行评分比较。结果:治疗组总有效率为82.5%,对照组为65.0%,2组比较,差异有统计学意义(P<0.05)。治疗前,2组ASQ、SNAP-Ⅳ评分比较,差异无统计学意义(P>0.05);治疗后,2组ASQ、SNAP-Ⅳ评分均较治疗前降低(P<0.05),且治疗组ASQ、SNAP-Ⅳ评分低于对照组(P<0.05)。结论:静灵口服液联合盐酸托莫西汀治疗ADHD可有效提高临床疗效,改善患儿注意力及控制力,有效缓解患儿临床症状。
Objective:To observe the clinical effect of Jingling oral liquid combined with atomoxetine hydrochloride for attention deficit hyperactivity disorder(ADHD).Methods:A total of 80 cases of ADHD patients were randomly divided into the control group and the treatment group,40 cases in each group.The control group was treated with atomoxetine hydrochloride,and the treatment group was additionally treated with Jingling oral liquid based on the treatment of the control group.After 12 weeks of treatment,the clinical effect in the two groups was observed;the scores of attention and controlling ability before and after treatment in the two groups were compared by the Conner Ages and Stages Questionnaire(ASQ)and the SNAP-Ⅳscale.Results:The total effective rate was 82.5%in the treatment group and 65.0%in the control group,the difference being significant(P<0.05).Before treatment,there was no significant difference being found in the comparison of the scores of ASQ and SNAP-Ⅳbetween the two groups(P>0.05).After treatment,the scores of ASQ and SNAP-Ⅳin the two groups were decreased when compared with those before treatment(P<0.05),and the scores in the treatment group were lower than those in the control group(P<0.05).Conclusion:The therapy of Jingling oral liquid combined with atomoxetine hydrochloride for ADHD can effectively improve the clinical effect,attention and controlling ability,and effectively alleviate the clinical symptoms of children.
作者
任莉
赵丽丽
朱平
REN Li;ZHAO Lili;ZHU Ping
出处
《新中医》
CAS
2021年第8期93-95,共3页
New Chinese Medicine
关键词
注意缺陷多动障碍
静灵口服液
盐酸托莫西汀
儿童
Attention deficit hyperactivity disorder
Jingling oral liquid
Atomoxetine hydrochloride
Children
